Hikma Overtakes Fresenius In US Injectables
Injectables Growth Across Regions In 2021 Accompanies Expansion Through Acquisitions
Hikma says it is now ranked second only to Pfizer in terms of US generic injectables volumes – overtaking rival Fresenius – as it continues to expand in the segment, including via recent acquisitions. Meanwhile, the firm is also laying the groundwork for a US biosimilars business.
